Literature DB >> 12616335

Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.

Caroline Nunn1, Philippe Schoeffter, Daniel Langenegger, Daniel Hoyer.   

Abstract

The two forms (DTyr8 and LTyr8) of the putative somatostatin sst2 receptor antagonist CYN 154806 (Ac-4NO2-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-D/LTyr-NH2) were investigated on recombinant human somatostatin receptors and endogenous guinea-pig ileum receptors. In radioligand binding studies using the agonist radioligands [125I]LTT-SRIF-28, [125I][Tyr10]cortistatin-14, [125I]CGP 23996 and [125I][Tyr3]octreotide in Chinese hamster lung fibroblast (CCL39) and Chinese hamster ovary (CHO) cells expressing human somatostatin receptors (hsst1-5), CYN 154806 binds to sst2 receptors with nanomolar affinity (pKD=8.14-8.89), 40- to 4500-fold higher than for sst1, sst3 or sst4. High affinity was also demonstrated for sst5 receptors, particularly for LTyr8CYN 154806 where the sst5 affinity was higher than for sst2 receptors when using [125I]CGP 23996 and [125I][Tyr3]octreotide. Functional properties of the compounds were examined in Chinese hamster ovary (CHO) cells expressing human sst2 receptors, in (1) inhibition of forskolin-stimulated adenylate cyclase, (2) stimulation of serum response element-driven luciferase expression and (3) [35S]guanosine 5'-O-(3-thiotriphosphate) ([35S]GTPS) binding. L- and DTyr8CYN 154806 showed full agonism at inhibition of forskolin-stimulated cAMP accumulation (pEC50=7.73 for both, Emax 104% and 78%, respectively), partial agonism at luciferase expression (pEC50=7.85 and 8.16, Emax=50% and 29%, respectively) and behaved as apparently silent antagonists at [35S]GTPS binding (no agonism observed, pKB=6.88 and 7.50, respectively). The agonist potential was confirmed in isolated guinea-pig ileum preparations via measurement of SRIF-induced inhibition of neurotransmission, where the L-isoform had marked agonism (pEC50=8.23, Emax=32%) whereas the D-isoform was apparently devoid of agonism. The present data suggest that CYN 154806 should be used with caution as an sst2 receptor antagonist tool, since it possesses intrinsic activity at sst2, and high affinity for both sst2 and sst5 receptors. The DTyr form, having lower intrinsic activity, especially in natural tissues, and greater selectivity for sst2 receptors, may be more reliable than LTyr CYN 154806.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12616335     DOI: 10.1007/s00210-002-0656-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

2.  Somatostatin coupling to adenylyl cyclase activity in the mouse retina.

Authors:  Barbara Pavan; Sara Fiorini; Massimo Dal Monte; Laura Lunghi; Carla Biondi; Paola Bagnoli; Davide Cervia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-12       Impact factor: 3.000

3.  Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells.

Authors:  Caroline Nunn; Davide Cervia; Daniel Langenegger; Laurent Tenaillon; Rochdi Bouhelal; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Somatostatin presynaptically inhibits both GABA and glutamate release onto rat basal forebrain cholinergic neurons.

Authors:  Toshihiko Momiyama; Laszlo Zaborszky
Journal:  J Neurophysiol       Date:  2006-03-29       Impact factor: 2.714

6.  Evidence That Endogenous Somatostatin Inhibits Episodic, but Not Surge, Secretion of LH in Female Sheep.

Authors:  Richard B McCosh; Brett M Szeligo; Michelle N Bedenbaugh; Justin A Lopez; Steven L Hardy; Stanley M Hileman; Michael N Lehman; Robert L Goodman
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

7.  Activation of somatostatin receptors in the globus pallidus increases rat locomotor activity and dopamine release in the striatum.

Authors:  A Marazioti; P M Pitychoutis; Z Papadopoulou-Daifoti; C Spyraki; K Thermos
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

8.  Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.

Authors:  Eva Ludvigsen; Mats Stridsberg; John E Taylor; Michael D Culler; Kjell Oberg; Eva T Janson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

9.  Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Caroline Nunn; Dominique Fehlmann; Daniel Langenegger; Edi Schuepbach; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  A functional comparison of recombinant and native somatostatin sst2 receptor variants in epithelia.

Authors:  N D Holliday; I R Tough; H M Cox
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.